The proposed 100% US tariffs on certain pharmaceuticals raise concerns about uncertainty in US–Taiwan trade relations. Any exclusion from preferential treatment could have broader implications. TaiwanPlus spoke with Darson Chiu, Director General of the Confederation of Asia-Pacific Chambers of Commerce and Industry, to discuss the implications and potential ripple effects.
